Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin® LAR®) in patients with acromegaly.

Marek BolanowskiWojciech ZgliczyńskiJerzy SowińskiAgata Bałdys-WaligórskaGrażyna Bednarek-TupikowskaPrzemysław WitekGrzegorz ZielińskiWłodzimierz LiebertLucyna SiemińskaElżbieta Andrysiak-MamosBogdan MarekDariusz KajdaniukJoanna MalickaVioletta RosiekAleksandra Jawiarczyk-PrzybyłowskaCsms Bpl Investigators

Published in: Endokrynologia Polska (2021)

We have shown good surgical outcome in patients with acromegaly after pre-treatment with somatostatin analogue, and good tolerance and safety of the therapy, supporting the national recommendation for pre-surgical treatment with long-acting somatostatin analogues in acromegaly patients.

Keyphrases

end stage renal disease
ejection fraction
neuroendocrine tumors
prognostic factors
peritoneal dialysis
quality improvement
combination therapy
molecular docking
mesenchymal stem cells
patient reported outcomes
molecular dynamics simulations